Introduction
============

Lung cancer is a malignant tumor that seriously threatens human health. In recent years, China has seen a simultaneous year-on-year increase in the number of lung cancer patients and the mortality ([@b1-ol-0-0-11675]). Lung cancer is the leading cause of death from cancer, the principal factor for cancer death in men, and the second cancer killer of women ([@b2-ol-0-0-11675]).

Advancements in science and technology have significantly improved the early diagnosis rate of lung cancer. Surgery is the preferred treatment for most patients, but the anesthesia and surgical trauma often cause a stress response. Trauma or surgical injury can activate immune inflammation and neuroendocrine reactions, leading to ischemic brain damage ([@b3-ol-0-0-11675]). The subsequent destruction of the blood-brain barrier causes brain dysfunction, leading to postoperative cognitive dysfunction (POCD) ([@b4-ol-0-0-11675]). As the main complication that contributes to disability and distress in millions of patients every year ([@b5-ol-0-0-11675]), POCD results in prolonged hospital stay, weakened physical functions, and increased mortality ([@b6-ol-0-0-11675],[@b7-ol-0-0-11675]), which severely damages the prognosis and quality of life of patients. So the rational use of anesthetic drugs is crucial for the treatment and prognosis of patients.

Dexmedetomidine is an α-2 adrenergic receptor agonist with sedative and analgesic effects, widely used for general anesthesia ([@b8-ol-0-0-11675]). Extubation during surgery can induce hemodynamic changes. Studies have reported that ([@b9-ol-0-0-11675],[@b10-ol-0-0-11675]) dexmedetomidine has a biphasic hemodynamic effect. It can regulate the release of norepinephrine and inhibit sympathetic activity, thereby reducing the release of inflammatory factors and stabilizing blood pressure. Dexmedetomidine can reduce the risk of hypertension and tachycardia in neurosurgical patients ([@b11-ol-0-0-11675],[@b12-ol-0-0-11675]) and is widely used clinically.

So far, there have been few reports on the effects of dexmedetomidine on brain function and hemodynamics in patients with lung cancer resection. Therefore, this study assessed the cognitive function and hemodynamic parameters in patients receiving dexmedetomidine anesthesia.

Patients and methods
====================

### Basic patient information

Eighty-seven patients with lung cancer undergoing lung cancer resection in Weifang People\'s Hospital (Weifang, China) from January 2014 to June 2018 were enrolled in this study. There were 41 patients undergoing conventional anesthesia in the control group and 46 patients undergoing conventional anesthesia and dexmedetomidine anesthesia in the research group. The two groups were not notably different regarding age, sex, and other basic information.

Inclusion criteria: Patients diagnosed with lung cancer and willing to receive surgical resection; patients not treated with radiotherapy or chemotherapy before; patients with no other malignant tumors. Exclusion criteria: Patients with liver and kidney dysfunction or communicative and cognitive impairment; patients who did not cooperate with the experiment. All patients and their families agreed to participate in the experiment and signed an informed consent form. This study was approved by the Ethics Committee of the hospital.

### Methods

The venous access was established at the beginning of the operation and the basic vital signs of patients were under close monitoring. In this study, propofol, midazolam, sufentanil, and cisatracurium besilate were used for conventional anesthesia. Patients in the control group underwent conventional anesthesia, while patients in the research group underwent conventional anesthesia and dexmedetomidine anesthesia (Sinopharm Group Guorui Medicine Co., Ltd.) through intravenous injection at an initial dose of 0.5 µg/kg and then at a fixed dose of 0.1 µg/kg-1 h-1. Elbow venous blood (5 ml) was drawn from all patients at T0, T1, T2, T3, and T4, respectively, and then centrifuged at 1,500 × g and 4°C for 10 min. Then the supernatant was collected and placed at −80°C in a refrigerator for later use. The expression levels of neuron-specific enolase (NSE) and S-100β in the serum of the patients were determined by enzyme-linked immunosorbent assay (ELISA) in strict accordance with the kit manuals. All kits were from Shanghai Guangrui Biological Co., Ltd.

Outcome measures. a) Hemodynamic parameters at different time points in the two groups: mean arterial pressure (MAP), heart rate (HR), and central venous pressure (CVP). b) Expression levels of NSE and S-100β at different time points in the two groups. c) Cognitive function indicated by the mini-mental state examination (MMSE) score in the two groups before the anesthesia and after the recovery from anesthesia. d) The case number of adverse reactions in the two groups. e) Correlation analysis between MMSE scores and serum NSE and S100β levels in the two groups.

Statistical analysis. Statistical analysis was performed on SPSS 20.0 software. The measurement data were expressed as the mean ± standard deviation (mean ± SD). t-test was used for intergroup comparison and paired t-test was used for intra-group comparison. The count data were expressed by n/% and intergroup comparison was performed by the χ^2^ test. Correlation analysis was performed using the Spearman correlation coefficient. The difference was considered statistically significant at P\<0.05.

Results
=======

### Comparison of the basic information between the two group

The two groups were not statistically different in age, BMI, and other basic information (P\>0.05) ([Table I](#tI-ol-0-0-11675){ref-type="table"}).

### Hemodynamic parameters at different time points in the two groups

In both the control group and the research group, the levels of MAP, HR, and CVP were statistically higher at T2 and T3 than those at T0 (all P\<0.05). The levels of MAP, HR, and CVP were statistically lower in the research group than those in the control group at T2 and T3 (P\<0.05) ([Table II](#tII-ol-0-0-11675){ref-type="table"}).

### The expression levels of serum NSE and S100β at different time points in the two groups

The levels of serum NSE and S100β protein in the research group and the control group increased at T2, T3, and T4, higher in control group than those in the research group at each time point, and the difference was statistically significant (P\<0.05) ([Table III](#tIII-ol-0-0-11675){ref-type="table"}).

### MMSE scores in the two groups before the anesthesia and after the recovery from anesthesia

The comparison of MMSE scores before anesthesia and after recovery from anesthesia showed no statistical difference between the two groups (P\>0.05) ([Table IV](#tIV-ol-0-0-11675){ref-type="table"}).

### Case number of adverse reactions in the two groups

One case of hypotension and 1 case of sinus bradycardia were reported in the research group, while 1 case of hypotension, 2 cases of sinus bradycardia, and 2 cases of sinus tachycardia were reported in the control group. The two groups were not statistically different in the total number of adverse reactions (P\>0.05) ([Table V](#tV-ol-0-0-11675){ref-type="table"}).

### Correlation analysis between MMSE scores and serum NSE and S100β levels

The MMSE scores of the two groups were positively correlated with the expression levels of serum NSE and S100β (P\<0.001) ([Fig. 1](#f1-ol-0-0-11675){ref-type="fig"}).

Discussion
==========

Good anesthesia can increase the success rate of surgery, reduce intraoperative inflammation and stress response, and improve the prognosis and recovery of postoperative organ function ([@b13-ol-0-0-11675]). Dexmedetomidine can inhibit neuronal discharge to achieve resistance to anxiety, suppress sympathetic nerve activity, reduce neuronal apoptosis, and alleviate the body\'s inflammatory response ([@b3-ol-0-0-11675]). Lung cancer resection, a common surgery for lung cancer treatment, leads to high risk of POCD in patients, which manifests as insanity, anxiety, and personality changes. These complications may be associated with factors such as anesthesia methods, types of surgery, and cognitive differences ([@b14-ol-0-0-11675]). Elderly patients general have other organ diseases such as cardiovascular disease, which will increase the risk of intubation. Therefore, monitoring the patient\'s hemodynamics and maintaining its stability is also important during the surgical anesthesia. This study aimed to explore the effect of dexmedetomidine on the brain function and hemodynamics in patients undergoing lung cancer resection.

In our study, MAP, HR, and CVP levels were significantly increased at T2 and T3 in both the control group and the research group, with higher levels in the research group, suggesting that the control group underwent great hemodynamic fluctuations, while dexmedetomidine effectively maintained the hemodynamic stability in the research group. The reason why dexmedetomidine contributes to hemodynamic stability may be that dexmedetomidine is involved in the systemic circulation so as to achieve sedation and analgesia and suppress the sympathetic nervous system activity. A previous study ([@b15-ol-0-0-11675]) reported that dexmedetomidine stabilized the hemodynamics of patients undergoing head and neck reconstruction. Another study ([@b16-ol-0-0-11675]) stated that intraoperative dexmedetomidine could better control postoperative MAP and provide a better analgesic effect for patients with craniotomy, which is consistent with the results of this study.

NSE is a highly specific marker for neuronal and peripheral neuroendocrine cells. When NSE is found in specific tissues under normal conditions, its increased body fluid levels may be accompanied by malignant proliferation and thus be valuable in the diagnosis, staging, and treatment of neuroendocrine tumors ([@b17-ol-0-0-11675],[@b18-ol-0-0-11675]). S100B is a calcium-binding protein found mainly in mature perivascular astrocyte cytoplasms ([@b19-ol-0-0-11675]). S100B protein and NSE are the most studied serum markers in the field of brain injury ([@b20-ol-0-0-11675]). In this study, serum expression levels of NSE and S100β were increased at T2, T3, and T4 in the research group and the control group. Serum expression levels of NSE and S100β protein were higher in the control group than those in the research group at each time point, and the MMSE scores of the two groups were positively correlated with the expression levels of NSE and S100β, suggesting that the severity of cognitive impairment was positively correlated with the expression levels of NSE and S100β. So we speculate that the expression levels of NSE and S100β can be used to monitor the postoperative cognitive impairment in patients. The study by Zhang *et al* ([@b21-ol-0-0-11675]) found that the increase in serum NSE and S100-β levels was correlated with the occurrence of cognitive impairment in patients with brain injury. Chaves *et al* ([@b22-ol-0-0-11675]) considered that higher S100β protein levels led to worse cognitive function, higher NSE level, and more severe brain atrophy. Therefore, the use of dexmedetomidine before anesthesia induction can reduce serum NSE and S100-β protein levels and improve the stability of cognitive functions in patients. No marked difference was shown in the total case number of adverse reactions and MMSE scores between the two groups before the anesthesia and after the recovery from anesthesia, indicating that dexmedetomidine is safe and worthy of clinical application and promotion.

In conclusion, the use of dexmedetomidine before the anesthesia induction can stabilize the hemodynamic parameters and certainly protect the brain function. However, the results of this study need to be further verified due to the small sample size.
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###### 

Comparison of basic information.

  Factors        Research group (n=41)   Control group (n=46)   t/χ^2^   P-value
  -------------- ----------------------- ---------------------- -------- ---------
  Age (year)     67.37±3.27              67.26±2.07             0.190    0.850
  BI (kg/m^2^)     21.3±2.45               21.5±2.36            0.388    0.699
  Sex                                                                    
    Male         21 (51.22)              24 (52.17)                      
    Female       20 (48.78)              22 (47.83)             0.008    0.939
  Hypertension                                                           
    Yes          18 (43.90)              20 (43.48)                      
    No           23 (56.10)              26 (56.52)             0.002    0.968
  Diabetes                                                               
    Yes          19 (46.34)              21 (45.65)                      
    No           22 (53.66)              25 (54.35)             0.004    0.949
  Hyperlipemia                                                           
    Yes          20 (48.78)              24 (52.17)                      
    No           21 (51.22)              22 (47.83)             0.099    0.752
  Smoking                                                                
    Yes          28 (68.29)              27 (58.70)                      
    No           13 (31.71)              19 (41.30)             0.859    0.354
  Drinking                                                               
    Yes          25 (60.98)              26 (56.52)                      
    No           16 (39.02)              20 (43.48)             0.177    0.673

###### 

Hemodynamic parameters at different time points in the two groups.

  Group                   Time   MAP /kPa                                                                                                                                           HR (beat/min)                                                                                                                                        CVP (mmHg)
  ----------------------- ------ -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Research group (n=41)   T0     10.2±1.6                                                                                                                                           82.61±7.34                                                                                                                                           88.61±5.25
                          T1     10.4±1.4                                                                                                                                           81.60±7.35                                                                                                                                           87.61±5.35
                          T2     11.0±1.5^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"},[e](#tfn5-ol-0-0-11675){ref-type="table-fn"}^   85.37±8.35^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"},[e](#tfn5-ol-0-0-11675){ref-type="table-fn"}^   91.61±6.25^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"},[e](#tfn5-ol-0-0-11675){ref-type="table-fn"}^
                          T3     11.4±1.4^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"},[e](#tfn5-ol-0-0-11675){ref-type="table-fn"}^   88.61±8.25^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"},[e](#tfn5-ol-0-0-11675){ref-type="table-fn"}^   93.61±6.35^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"},[e](#tfn5-ol-0-0-11675){ref-type="table-fn"}^
                          T4     10.3±1.3^[c](#tfn3-ol-0-0-11675){ref-type="table-fn"},[d](#tfn4-ol-0-0-11675){ref-type="table-fn"}^                                                83.60±7.34^[c](#tfn3-ol-0-0-11675){ref-type="table-fn"},[d](#tfn4-ol-0-0-11675){ref-type="table-fn"}^                                                86.61±5.45^[c](#tfn3-ol-0-0-11675){ref-type="table-fn"},[d](#tfn4-ol-0-0-11675){ref-type="table-fn"}^
  Control group (n=46)    T0     10.4±1.2                                                                                                                                           81.95±8.43                                                                                                                                           87.61±5.23
                          T1     10.5±1.3                                                                                                                                           80.95±8.43                                                                                                                                           88.61±5.35
                          T2     11.8±1.6^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"}^                                                95.38±7.68^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"}^                                                95.61±6.53^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"}^
                          T3     12.4±1.5^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"}^                                                97.38±7.58^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"}^                                                97.61±6.46^[a](#tfn1-ol-0-0-11675){ref-type="table-fn"},[b](#tfn2-ol-0-0-11675){ref-type="table-fn"}^
                          T4     10.3±1.6^[c](#tfn3-ol-0-0-11675){ref-type="table-fn"},[d](#tfn4-ol-0-0-11675){ref-type="table-fn"}^                                                82.38±8.32^[c](#tfn3-ol-0-0-11675){ref-type="table-fn"},[d](#tfn4-ol-0-0-11675){ref-type="table-fn"}^                                                86.61±5.34^[c](#tfn3-ol-0-0-11675){ref-type="table-fn"},[d](#tfn4-ol-0-0-11675){ref-type="table-fn"}^

P\<0.05 when compared with T0 within the group

P\<0.05 when compared with T1 within the group

P\<0.05 when compared with T2 within the group

P\<0.05 when compared with T3 within the group

P\<0.05 when compared with T4 within the group. MAP, mean arterial pressure; HR, heart rate; CVP, central venous pressure.

###### 

Expression levels of serum NSE and S100β at different time points in the two groups.

  Group                   Time   NSE (µg/l)                                                                                                                                           S100β (µg/l)
  ----------------------- ------ ---------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Research group (n=41)   T0     0.14±0.03                                                                                                                                            5.67±1.56
                          T1     0.15±0.04                                                                                                                                            5.72±1.62
                          T2     0.76±0.13^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"},[e](#tfn10-ol-0-0-11675){ref-type="table-fn"}^   6.62±1.78^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"},[e](#tfn10-ol-0-0-11675){ref-type="table-fn"}^
                          T3     0.82±0.18^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"},[e](#tfn10-ol-0-0-11675){ref-type="table-fn"}^   6.89±1.93^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"},[e](#tfn10-ol-0-0-11675){ref-type="table-fn"}^
                          T4     0.98±0.21^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"}--[e](#tfn10-ol-0-0-11675){ref-type="table-fn"}^                                               7.79±1.98^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"}--[e](#tfn10-ol-0-0-11675){ref-type="table-fn"}^
  Control group (n=46)    T0     0.13±0.03                                                                                                                                            5.68±1.46
                          T1     0.15±0.05                                                                                                                                            5.82±1.36
                          T2     1.26±0.13^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"}^                                                 8.67±1.16^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"}^
                          T3     1.30±0.12^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"}^                                                 8.87±1.26^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"},[b](#tfn7-ol-0-0-11675){ref-type="table-fn"}^
                          T4     1.43±0.15^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"}--[d](#tfn9-ol-0-0-11675){ref-type="table-fn"}^                                                9.37±1.36^[a](#tfn6-ol-0-0-11675){ref-type="table-fn"}--[d](#tfn9-ol-0-0-11675){ref-type="table-fn"}^

P\<0.05 when compared with T0 within the group

P\<0.05 when compared with T1 within the group

P\<0.05 when compared with T2 within the group

P\<0.05 when compared with T3 within the group

P\<0.05 when compared with T4 within the group. NSE, neuron-specific enolase.

###### 

MMSE scores in the two groups before the anesthesia and after the recovery from anesthesia.

  Group                                Research group (n=41)   Control group (n=46)   t       P-value
  ------------------------------------ ----------------------- ---------------------- ------- ---------
  Before the anesthesia                28.54±4.34              28.48±4.25             0.065   0.948
  After the recovery from anesthesia   27.34±2.45              27.21±3.11             0.215   0.831

MMSE, mini-mental state examination.

###### 

Case number of adverse reactions in the two groups.

  Group                               Research group (n=41)   Control group (n=46)   χ^2^    P-value
  ----------------------------------- ----------------------- ---------------------- ------- ---------
  Hypotension                         1 (2.44)                1 (2.17)               0.007   0.934
  Sinus bradycardia                   1 (2.44)                2 (4.35)               0.237   0.626
  Sinus tachycardia                   0                       2 (4.35)               1.825   0.177
  Total number of adverse reactions   2 (4.88)                5 (10.87)              1.052   0.305
